Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25409646 | 1.00 | LMNA (0.40) | LMNAUSP2HTTSMN1; SMN2NPC1 | |
| SCHEMBL34475226 | 0.85 | LMNA (0.42) | LMNAUSP2HTTSMN1; SMN2NPC1 | |
| SCHEMBL25413364 | 0.82 | HTT (0.43) | LMNAUSP2HTTSMN1; SMN2NPC1 | |
| SCHEMBL25413369 | 0.82 | HTT (0.43) | LMNAUSP2HTTSMN1; SMN2NPC1 | |
| SCHEMBL25413866 | 0.81 | USP2 (0.38) | LMNAUSP2HTTSMN1; SMN2NPC1 | |
| SCHEMBL29115934 | 0.80 | HTT (0.44) | LMNAUSP2HTTSMN1; SMN2NPC1 | |
| SCHEMBL34473425 | 0.79 | CASP1 (0.42) | LMNAUSP2HTTSMN1; SMN2NPC1 | |
| SCHEMBL21935482 | 0.79 | ALDH1A1 (0.47) | HTTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL17706677 | 0.78 | MAPT (0.51) | LMNAUSP2HTTSMN1; SMN2NPC1 | |
| SCHEMBL31233954 | 0.78 | MEN1 (0.43) | LMNAUSP2HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741423-A2 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | Mablink Bioscience (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-20250302978-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | MABLINK BIOSCIENCE (FR) | 2025-10-02 | — | — | US | disclosed |
| US-20240216525-A1 | ENZYME-TRIGGERED SELF-REACTING LINKER HAVING IMPROVED PHYSICOCHEMICAL AND PHARMACOLOGICAL PROPERTIES | MABLINK BIOSCIENCE (FR) | 2024-07-04 | — | — | US | disclosed |
| EP-4313157-A1 | ENZYME-TRIGGERED SELF-REACTING LINKER HAVING IMPROVED PHYSICOCHEMICAL AND PHARMACOLOGICAL PROPERTIES | Mablink Bioscience (FR) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157102-A | Enzyme-triggered self-reacting linkers with improved physicochemical and pharmacological properties | 马布林克生物科学公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023170247-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | MABLINK BIOSCIENCE (FR) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216525-A1 | ENZYME-TRIGGERED SELF-REACTING LINKER HAVING IMPROVED PHYSICOCHEMICAL AND PHARMACOLOGICAL PROPERTIES | DDC, BCHE, ENGASE | LMNA 1320/4885USP2 463/4885HTT 3889/4885 |
| US-20250302978-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | FOLR1, FOLR2, FCGR2A | LMNA 4619/4885USP2 4145/4885HTT 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.